21:55 , Jul 24, 2019 |  BC Innovations  |  Distillery Therapeutics

Simultaneous CLEC5A and TLR2 inhibition for dengue

DISEASE CATEGORY: Infectious disease INDICATION: Dengue fever; viral hemorrhagic fever Simultaneously blocking CLEC5A and TLR2, both pattern recognition receptors linked to microbial infections, could improve survival following dengue virus infection. The inflammatory response to dengue...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Systemic inflammatory response syndrome (SIRS); shock/trauma C-type lectin domain family 5 member A (CLEC5A; MDL1); phosphoinositide 3-kinase (PI3K); spleen tyrosine kinase (SYK); protein kinase B...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease IL-17C; IL-17 receptor E (IL-17RE) Mouse studies suggest antagonizing IL-17C or its receptor, IL-17RE, could help treat autoimmune diseases. In mice with...
07:00 , Mar 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) C-type lectin domain 5 member A (CLEC5A; MDL1) Studies in tissue samples and in mice suggest that inhibiting MDL1 could help...